413 related articles for article (PubMed ID: 25406834)
41. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
42. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
Grauslund M; Thougaard AV; Füchtbauer A; Hofland KF; Hjorth PH; Jensen PB; Sehested M; Füchtbauer EM; Jensen LH
Mol Pharmacol; 2007 Oct; 72(4):1003-14. PubMed ID: 17622580
[TBL] [Abstract][Full Text] [Related]
43. Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model.
Frank NE; Cusack BJ; Talley TT; Walsh GM; Olson RD
Invest New Drugs; 2016 Dec; 34(6):693-700. PubMed ID: 27581956
[TBL] [Abstract][Full Text] [Related]
44. Identification of the molecular basis of doxorubicin-induced cardiotoxicity.
Zhang S; Liu X; Bawa-Khalfe T; Lu LS; Lyu YL; Liu LF; Yeh ET
Nat Med; 2012 Nov; 18(11):1639-42. PubMed ID: 23104132
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
46. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
48. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
[TBL] [Abstract][Full Text] [Related]
49. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
50. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
51. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
52. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells.
Saffi J; Agnoletto MH; Guecheva TN; Batista LF; Carvalho H; Henriques JA; Stary A; Menck CF; Sarasin A
DNA Repair (Amst); 2010 Jan; 9(1):40-7. PubMed ID: 19926538
[TBL] [Abstract][Full Text] [Related]
53. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
54. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues.
Duran GE; Lau DH; Lewis AD; Kühl JS; Bämmler TK; Sikic BI
Cancer Chemother Pharmacol; 1996; 38(3):210-6. PubMed ID: 8646794
[TBL] [Abstract][Full Text] [Related]
55. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations.
Mosesso P; Pepe G; Ottavianelli A; Schinoppi A; Cinelli S
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():14-8. PubMed ID: 26520368
[TBL] [Abstract][Full Text] [Related]
56. Bioflavonoids as poisons of human topoisomerase II alpha and II beta.
Bandele OJ; Osheroff N
Biochemistry; 2007 May; 46(20):6097-108. PubMed ID: 17458941
[TBL] [Abstract][Full Text] [Related]
57. TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.
Moretti E; Desmedt C; Biagioni C; Regan MM; Oakman C; Larsimont D; Galardi F; Piccart-Gebhart M; Sotiriou C; Rimm DL; Di Leo A
Future Oncol; 2013 Oct; 9(10):1477-87. PubMed ID: 24106899
[TBL] [Abstract][Full Text] [Related]
58. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
Bau JT; Kurz EU
Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
[TBL] [Abstract][Full Text] [Related]
59. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Boland MP; Fitzgerald KA; O'Neill LA
J Biol Chem; 2000 Aug; 275(33):25231-8. PubMed ID: 10940316
[TBL] [Abstract][Full Text] [Related]
60. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
